TOPERA MEDICAL AT HEART RHYTHM SOCIETY 2012 SCIENTIFIC SESSIONS

Topera in the news

• "... the potential to change the standard of care in mapping directed AF ablation. Early data in patients with principally persistent AF was very impressive..."

  UBS Investment Research

  Bruce Nudell, UBS

  March 28, 2011

• "Targeted, single procedure ablation at identified AF sources increased the long-term freedom from AF by 70 percent over the existing standard of care."

  Industry Alert Medical Devices & Supplies. HRS Late Breaking Abstracts

  Kristen Stewart, Deutsche Bank

  May 5, 2011

• "The single‐procedure efficacy of FIRM‐guided ablation was 84.3% at 2 years, results that we consider impressive given conventional outcomes (in this study 50.5%)."

  Industry Alert Medical Devices & Supplies. HRS Late Breaking Abstracts

  Kristen Stewart, Deutsche Bank

  May 5, 2011

• "Current atrial fibrillation ablation techniques target regions of the heart where the abnormal rhythms associated with the disease may initially be triggered, but not the actual locations of the irregular activity. That could change, however, based on research presented last week employing a novel diagnostic mapping system to locate the electrical building blocks of AF rhythms for ablation."

  Ablating AF At Its Source: Novel Diagnostic Mapping Tool Linked To Long-Term Benefit.

  David Filmore, Gray Sheet

  May 9, 2011

• "the CONFIRM Trial, presented by Dr. Sanjiv Narayan and colleagues, could potentially represent a paradigm shift in our understanding and ablative treatment approach of persistent atrial fibrillation (AF). This study could dramatically impact AF management..."

  Letter from the Editor-in-Chief. The Journal of Innovations in Cardiac Rhythm Management.

  John Day

  June 29, 2011

• "The results are even more impressive for several reasons: (1) 84% of the FIRM patients were monitored by implantable loop monitors, which is a very precise means to accurately detect episodes of AF; (2) this data described two year outcomes, which speaks to the durability of the approach; (3) this data was accomplished with a single procedure and is considerably better than the conventional method. (4) the success in treating patients in the trial with persistent AF is remarkable; typically this patient subset achieves the poorest outcomes with catheter ablation and often require a second or third catheter ablation to overcome their AF and return to normal sinus rhythm; (5) FIRM rapidly terminated AF predominantly to normal sinus rhythm in less than 10 minutes prior to conventional ablation."

  AF still at the heart of annual HRS meeting.

  Medical Devices Daily. Larry Haimovitch

  May 10, 2011

• "Heart Rhythm Society President Douglas L. Packer commented that because AF ablation procedures take a substantial amount of time, a technical advance that shortens that time "would be of enormous significance to operators, patients, and payers."

  New Paradigm in AF Therapy Is Promising.

  Internal Medicine News. Bruce Jancin

  May 25, 2011.

• "…an A-Fib diagnostic tool that we believe could ultimately help drive increasing ablation penetration and sustainable double-digit market growth longer term through improved diagnostic capabilities and potentially shorter overall procedure times."

  Medical Devices - Cardiology. HRS Wrap-Up: Lots of New Products but ICD Market Pressures Too.

  Rick Wise (Leerink Swann)

  May 10, 2011.

• "Topera grabs the spotlight......a significant improvement over standard of care ablation strategies. If the results continue to be positive in future studies, Topera will dramatically change the field of AFib."

  Medical Devices & Hospital Supplies: Top takeaways from Heart Rhythm Society (HRS) conference.

  Tao Levy (Collins Stewart)

  May 9, 2011.

• "During the press conference, Doug Packer, MD, of the Mayo Clinic, Rochester, MN, and outgoing HRS president, commented on the trial, noting that the technology enables physicians to map arrhythmias based on real physiology, unlike the anatomical methods currently in use, and it has the potential to shorten procedure times. Anything that can achieve the latter goal would offer an “enormous benefit,” he said."

  HRS 2011: What’s hot, what’s not,in AF ablation.

  Medtech Insight. Mary Thompson

• "The market opportunity is huge, physician interest is high, and the clinical and regulatory hurdles are significantly less than any other meaningful emerging medical technology that we can think of outside of Topera’s new AF technology."

  Industry Overview.

  Bob Hopkins (Bank of America Merrill Lynch )

  October 6, 2011.

• "Topera Medical---developing a mapping system to isolate arrhythmias---could be a game-changer."

  Medical Devices-Cardiology MEDACorp Pulse Call: Continued Pressures on ICDs, AF Growth Continues.

  Rick Wise (Leerink Swann)

  October 17th, 2010.

• "If Topera were to be acquired by one of the catheter ablation companies, it could enable that company to become the leading player in the catheter ablation market, rapidly increase the number of catheter ablation procedures performed, and potentially displace the other competitors."

  Medical Devices & Hospital Supplies: Topera's novel AFib targeting technology receives FDA clearance.

  Tao Levy (Collins Stewart)

  October 6, 2011.